All grants

Austin FY 2021 – FY 2023 EDA Planning and Local Technical Assistance

Philadelphia FY 2021 – FY 2023 EDA Planning and Local Technical Assistance

Leading Edge Acceleration Projects for Health IT (LEAP)

FDA OMHHE Convener for Racial & Ethnic minority Acceleration Consortium for Health Equity (REACH)

Manufactured Foods Flexible Funding Model (MF-FFM)

FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)

Rapid Response Team (RRT) Cooperative Agreement

State Electronic Crash Data Collection

FY 2025 EDA Public Works and Economic Adjustment Assistance Programs

FY 2023 Disaster Supplemental

Data Standards for Tobacco Research and Scientific Review Phase 2

DRAFT Community Noise Mitigation Program

Integrating Machine Learning with Computational Fluid Dynamics Models of Orally Inhaled Drug Products (U01) Clinical Trials Not Allowed

Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional

Utilizing Real-World Data and Algorithmic Analyses to Assess Post-Market Clinical Outcomes in Patients Switching Amongst Therapeutically Equivalent Complex Generic Drug Products and Reference Listed Drugs (U01) Clinical Trial Not Allowed

Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required)

Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional

Identification of Drug-related and Formulation-Related Factors that Result in Alcohol Dose Dumping of Modified Release Oral Drug Products (U01) Clinical Trial Not Allowed

Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed

Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)